Bristol Myers gets positive EMA opinion for repotrectinib
Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
pharmaphorum4y
Roche's NTRK tumour-agnostic therapy Rozlytrek approved in Europe
Last September Bayer’s Vitrakvi became the first NTRK inhibitor class drug approved in Europe and the first ever drug licensed to tackle tumours solely based on their genetic signature ...
pharmaphorum5d
FDA widens label for BMS’ cancer drug Augtyro
Bristol-Myers Squibb has claimed FDA approval for a new ... Specifically, BMS’ drug can be used in patients aged 12 and over with NTRK-positive tumours that are locally advanced or metastatic ...
Targeted Oncology7d
Emerging TRK Inhibitors Are Explored Across Cancer Settings
Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...
GlobalData on MSN2mon
FDA grants approval to Illumina’s cancer biomarker test with two CDx indications
Illumina has secured approval from the US Food and Drug Administration (FDA ... when neurotrophic tyrosine receptor kinase ...